Heron Therapeutics, Inc.
0J4V.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$76.87M
Close$
Share Statistics
| Market cap | $76.87 Million |
|---|---|
| Enterprise Value | $204.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.67 |
| Outstanding Shares | 190,335,000 |
Return
| Return on Equity | -492.89% |
|---|---|
| Return on Assets | -13.50% |
| Return on Invested Capital | -10.18% |
Valuation & Multiples
| P/E Ratio | -2.17 |
|---|---|
| PEG | -1.66 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.35 |
| Enterprise Value to EBIT | -12.55 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.73 |
| Debt to Equity | 21.48 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$42.19 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$37.50 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Heron Therapeutics Inc
128 employees
CEO: Barry Quart Heron Therapeutics, Inc. is a biotechnology firm dedicated to developing innovative therapeutic solutions for significant unmet patient needs. At the heart of its pipeline is the proprietary Biochronomer drug delivery system. This techno...